All In Biotech

Drug Trial Radar · NCT07504588

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

A Randomized Phase II Trial of Sacituzumab Govitecan-HZIY (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

87

Planned (sponsor's estimate)

Start

Sep 24, 2026

Primary completion

Apr 12, 2029

Study completion Apr 12, 2029

Sponsor

Sponsor type
NIH
First posted
Apr 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.

Conditions

  • Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
  • Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma
  • Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma
  • Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma
  • Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma

Interventions

  • Anti-VEGF Monoclonal AntibodyBiological

    Given IV

  • BevacizumabBiological

    Given IV

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • CarboplatinDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT

  • Echocardiography TestProcedure

    Undergo ECHO

  • GemcitabineDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Pegylated Liposomal Doxorubicin HydrochlorideDrug

    Given IV

  • Sacituzumab GovitecanBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: From randomization to either progressive disease or death from any cause, assessed up to 5 years

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Highlands Oncology Group - Fayetteville

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Carle at The Riverfront

    Danville, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Recruiting

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois · Recruiting

  • Carle BroMenn Medical Center

    Normal, Illinois · Recruiting

  • Carle Cancer Institute Normal

    Normal, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • Goshen Center for Cancer Care

    Goshen, Indiana · Recruiting

  • Mercy Hospital

    Cedar Rapids, Iowa · Recruiting

  • Oncology Associates at Mercy Medical Center

    Cedar Rapids, Iowa · Recruiting

  • Our Lady of the Lake Physician Group

    Baton Rouge, Louisiana · Recruiting

  • Our Lady of the Lake Medical Oncology

    Baton Rouge, Louisiana · Recruiting

  • Mercy Hospital Springfield

    Springfield, Missouri · Recruiting

  • Community Hospital of Anaconda

    Anaconda, Montana · Recruiting

  • Billings Clinic Cancer Center

    Billings, Montana · Recruiting

  • Bozeman Health Deaconess Hospital

    Bozeman, Montana · Recruiting

  • Benefis Sletten Cancer Institute

    Great Falls, Montana · Recruiting

  • Logan Health Medical Center

    Kalispell, Montana · Recruiting

  • Community Medical Center

    Missoula, Montana · Recruiting

  • Monmouth Medical Center

    Long Branch, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Community Medical Center

    Toms River, New Jersey · Recruiting

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • University of Virginia Cancer Center

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.